Title |
Developing a new generation of breast cancer clinical gene expression tests
|
---|---|
Published in |
Breast Cancer Research, July 2014
|
DOI | 10.1186/bcr3688 |
Pubmed ID | |
Authors |
Zuzana Kos, Torsten O Nielsen |
Abstract |
When treatment decisions are based purely on clinicopathological factors, many women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative cancers are overtreated. Gene expression profiles are valuable clinical tools that stratify the recurrence risk to identify patients most likely to benefit from adjuvant systemic therapies. Building upon greater understanding of tumor biology and more rigorous approaches to validation (including independent studies with a high level of evidence), several second-generation multigene tests have been developed. In the previous issue, Martin and colleagues report the third clinical validation study for EndoPredict, a distributed assay to assess risk of distant recurrences in estrogen receptor-positive/human epidermal growth factor receptor 2-negative women. The authors confirm the assay's independent prognostic value in premenopausal and postmenopausal, node-positive women treated with contemporary chemotherapy followed by endocrine therapy. EndoPredict did not, however, predict benefit from adding paclitaxel. Predictive signatures for selecting among chemotherapy regimens remain an area needing further development. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 27 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 7 | 26% |
Other | 5 | 19% |
Student > Bachelor | 3 | 11% |
Student > Master | 3 | 11% |
Student > Ph. D. Student | 2 | 7% |
Other | 5 | 19% |
Unknown | 2 | 7% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 37% |
Agricultural and Biological Sciences | 6 | 22% |
Biochemistry, Genetics and Molecular Biology | 4 | 15% |
Chemical Engineering | 1 | 4% |
Economics, Econometrics and Finance | 1 | 4% |
Other | 1 | 4% |
Unknown | 4 | 15% |